Analysts Set Cryoport, Inc. (NASDAQ:CYRX) Target Price at $11.50

Cryoport, Inc. (NASDAQ:CYRX) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $11.50.

A number of equities analysts have issued reports on CYRX shares. Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of Cryoport in a research report on Wednesday, March 5th. Guggenheim initiated coverage on Cryoport in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 target price on the stock.

Insiders Place Their Bets

In other news, CEO Jerrell Shelton sold 4,620 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the sale, the chief executive officer now directly owns 765,399 shares of the company’s stock, valued at $4,814,359.71. This represents a 0.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 14,431 shares of company stock worth $80,884. Company insiders own 10.10% of the company’s stock.

Institutional Trading of Cryoport

A number of hedge funds and other institutional investors have recently modified their holdings of CYRX. Point72 Asia Singapore Pte. Ltd. grew its holdings in Cryoport by 148.7% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after purchasing an additional 2,120 shares during the period. Lazard Asset Management LLC purchased a new stake in shares of Cryoport in the 4th quarter worth approximately $51,000. Avanza Fonder AB purchased a new stake in shares of Cryoport in the 4th quarter worth approximately $64,000. Quarry LP purchased a new stake in shares of Cryoport in the 4th quarter worth approximately $69,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Cryoport in the third quarter worth $82,000. 92.90% of the stock is owned by hedge funds and other institutional investors.

Cryoport Price Performance

Shares of Cryoport stock opened at $5.84 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. The business’s 50 day simple moving average is $6.92 and its two-hundred day simple moving average is $7.42. The stock has a market capitalization of $291.47 million, a P/E ratio of -1.73 and a beta of 1.67. Cryoport has a one year low of $4.58 and a one year high of $20.11.

Cryoport (NASDAQ:CYRX) last issued its earnings results on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The firm had revenue of $59.53 million during the quarter, compared to analysts’ expectations of $58.71 million. During the same period in the previous year, the firm earned ($0.29) earnings per share. Analysts forecast that Cryoport will post -0.99 EPS for the current year.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.